In this phase II study , patients with stage IIIB/IV non-small-cell lung cancer were randomly assigned ( @:@:@ ) to receive LY@ ( @ mg twice daily -LSB- @ LY@ -RSB- or @ mg twice daily -LSB- @ LY@ -RSB- ) or placebo for @ days , followed by concurrent cisplatin ( @ mg/m@ ; day @ ) and gemcitabine ( @ mg/m@ ; days @ and @ ) , every @ days.The primary endpoint was progression-free survival , ( PFS ) , with @ % power to detect @ % improvement compared with placebo ( @ months ) .